PRRTInfo.org - A Resource for Patients Considering PRRT Treatment.

PRRTinfo.org is a site for patients considering PRRT (Peptide Receptor Radionuclide Therapy) treatment in Germany written by patients for patients. While much of this information can be used by patients seeking treatment at any PRRT Center worldwide, this site focus is on the treatment as provided by Dr. Richard Baum and his team at the Zentralklinik Bad Berka in Bad Berka, Germany. We also provide links to a select number of other medical centers that offer PRRT which can be found here.As with any site that offers information on treatment or travel, please confirm medical information with your medical team, as well as any travel information with the travel providers.

AAA announced on September 29, 2017 that the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide* (Lutathera®) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA.

AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare

The results from the first randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.

PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.

At the 2nd Theranostics World Congress there was progress towards the treatment of metastatic prostate cancer using a Theranostics approach. At the 3rd Theranostics World Congress that progress continued from the bench and to the bedside.

This video is an overview of the treatment and management of metastatic prostate cancer using a Theranostic Approach.